IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response

Bendig S, Hartmann AM, Wessels W, Beder T, Kim R, Passet M, Gao Q, Wolgast N, Horns JM, Alves Santos L, Iben K, Steffen FD, Cantoni L, Kehden B, Chitadze G, Künstner A, Busch H, Bornhauser B, Bourquin JP, Leguay TTL, Boissel N, Gökbuget N, Iacobucci I, Mullighan CG, Clappier E, Baldus CD, Brüggemann M, Bastian L.